8-K: Faraday Future Invests $41M in Qualigen for Crypto Venture

Faraday Future Intelligent Electric Inc. announces a strategic $41 million investment in Qualigen Therapeutics, Inc. to launch a new crypto and Web3-related business, with significant governance changes and a rebranding for Qualigen.

Summary

• Faraday Future Intelligent Electric Inc. (FFAI) is investing approximately $40.7 million in Qualigen Therapeutics, Inc. (QLGN) through a Private Investment in Public Equity (PIPE) transaction.
• The primary objective of this investment is for Qualigen to establish and grow a new crypto and Web3-related business, with Qualigen expected to rebrand as CXC10.
• Faraday Future's direct investment is approximately $30 million, which will result in approximately 55% beneficial ownership of Qualigen's outstanding common stock on a pro forma basis.
• FF Founder and Global Co-CEO YT Jia is personally investing approximately $4 million (via an FFGP loan), securing about 7% ownership in Qualigen's common stock, with a two-year lock-up on his shares.
• The total financing for Qualigen, including contributions from other investors such as SIGN Foundation, is approximately $41 million.
• The closing of this transaction is anticipated to occur on or about September 29, 2025, contingent upon the satisfaction or waiver of customary closing conditions and Qualigen's stockholder approval.
• Faraday Future's stockholders approved an amendment to the company's Charter to increase the number of authorized common stock by 65,225,672 shares, from 167,245,313 to 232,470,985 shares (a 39% increase).
• Stockholders also approved an increase in authorized preferred stock by 5,031,000 shares, from 12,900,000 to 17,931,000 shares, bringing the total authorized shares to 250,401,985.
• The issuance of FFAI Class A Common Stock to holders of certain convertible notes and warrants was approved by stockholders.
• A proposal to change Faraday Future's name from "Faraday Future Intelligent Electric Inc." to "Faraday Future AI Electric Vehicle Inc." was not approved by stockholders.
• Stockholders approved an amendment to the 2021 Stock Incentive Plan to increase the number of shares available for issuance by an additional 9,500,000 shares.
• Faraday Future's Series A Preferred Stock was eliminated following the automatic redemption of all outstanding shares after the Special Meeting.

Sentiment

Score: 8

Explanation: The filing outlines a significant strategic investment and diversification into the high-growth crypto and Web3 sectors, coupled with positive updates on the core EV product (FX Super One) and successful stockholder approvals for key financial flexibility measures. The reported unrealized gain on the C10 Treasury is also a positive indicator. The only minor negative is the failed name change proposal, which does not detract significantly from the overall positive strategic direction and operational progress.

Positives

• The strategic investment in Qualigen Therapeutics for a crypto and Web3 business creates potential "Dual Flywheel synergy and Dual Bridge empowerment" for Faraday Future, connecting EAI with crypto and bridging Web2 with Web3.
• This diversification is expected to unlock new financing channels and maximize stockholder value for Faraday Future without additional dilution to its stockholders for the crypto-related business.
• Qualigen's C10 Treasury reported an unrealized gain of approximately 7% as of September 18, 2025, demonstrating positive initial performance in its crypto asset allocations and outperforming the C10 index overall.
• Faraday Future stockholders approved significant increases in authorized common and preferred stock, providing the company with greater flexibility for future capital raises or strategic initiatives.
• The approval to increase shares available under the 2021 Stock Incentive Plan by 9,500,000 shares enhances Faraday Future's ability to attract and retain talent through equity compensation.
• Progress on the FX Super One MPV continues, with its first global product launch on July 17, 2025, and the first vehicle roll-off expected by year-end in the U.S., followed by a Middle East Final Launch by end of October and first deliveries in November.

Negatives

• Faraday Future's stockholders did not approve the proposed amendment to change the company's name to "Faraday Future AI Electric Vehicle Inc."
• The investment in Qualigen and its new crypto strategy introduces exposure to the inherent volatility and regulatory uncertainty associated with cryptocurrency investments, which could impact financial performance.

Risks

• Ability to consummate the investment in Qualigen Therapeutics in a timely manner, if at all.
• Qualigen's ability to raise future capital on attractive terms, if at all.
• Faraday Future's ability to control the management and operations of the separate listed entity (Qualigen/CXC10).
• Faraday Future's ability to successfully execute on a new crypto-based strategy.
• Faraday Future's ability to raise funds to support a new crypto-based strategy.
• Inherent volatility and regulatory uncertainty associated with cryptocurrency investments.
• Current and potential litigation involving Faraday Future.
• The result of future financing efforts, the failure of any of which could result in Faraday Future seeking protection under the Bankruptcy Code.
• General economic and market conditions impacting demand for Faraday Future's products.
• Circumstances outside of Faraday Future's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest.
• Faraday Future's ability to develop and protect its technologies.
• Faraday Future's ability to protect against cybersecurity risks.
• Faraday Future's ability to secure the necessary funding to execute on the FX strategy.
• Faraday Future's ability to secure agreements with OEMs that are necessary to execute on the FX strategy.
• Faraday Future's ability to homologate FX vehicles for sale in the U.S., the Middle East, or elsewhere.
• Faraday Future's ability to continue as a going concern and improve its liquidity and financial position.
• Faraday Future's ability to pay its outstanding obligations.
• Faraday Future's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements.
• Faraday Future's limited operating history and the significant barriers to growth it faces.
• Faraday Future's history of losses and expectation of continued losses.

Future Outlook

Qualigen Therapeutics is expected to rebrand as CXC10, focusing entirely on three growth engines in crypto and Web3 ecosystem buildup, aiming to become a top U.S. public company bridging Web2 and Web3, as well as AI and crypto. These growth engines include the C10 value anchor (C10 Treasury, C10 Index, potential C10 ETF), the BesTrade DeAI Agent, and ecosystem tokens (C10 stablecoin, EAI+Crypto Dual-Bridge RWA product). Faraday Future anticipates this strategic move will create "Dual Flywheel synergy and Dual Bridge empowerment" connecting EAI with crypto and bridging Web2 with Web3. The FX Super One MPV is on track for its first vehicle roll-off by year-end in the U.S., with a Middle East Final Launch by end of October and first deliveries expected in November.

Management Comments

• "This strategic investment represents an important milestone in our evolution. I believe that FFAI will truly become a company powered by Dual Flywheel synergy and Dual Bridge empowerment—connecting EAI with crypto, and bridging Web2 with Web3." YT Jia, Founder and Global Co-CEO of Faraday Future.
• "This is a very exciting day for all stakeholders of Qualigen Therapeutics. The company will be embracing the new economy and technology which will reshape the future. The board unanimously voted to move forward with this transformative transaction and stand behind the leadership FF brings to our company." Kevin A. Richardson, CEO of Qualigen Therapeutics.
• "I believe that as these products gradually come to life, FFAI will truly become a company powered by Dual Flywheel synergy and Dual Bridge empowerment—connecting EAI with Crypto, and bridging Web2 with Web3. Together, they have massive potential and will help maximize value for both stockholders and token holders." YT Jia.

Industry Context

This announcement positions Faraday Future to diversify its business beyond electric vehicles into the rapidly evolving cryptocurrency and Web3 sectors, leveraging its "Dual Flywheel & Dual Bridge Eco Strategy." By investing in Qualigen Therapeutics and transforming it into a crypto-focused entity (CXC10), Faraday Future aims to capitalize on the growing interest in digital assets and decentralized technologies. This move could be seen as an attempt to create new revenue streams and financing opportunities, potentially mitigating some of the capital-intensive challenges often faced by EV startups. The focus on AI integration in both EV and crypto strategies aligns with broader technological trends.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies or projects in the broader EV or crypto industries.
• Qualigen's C10 Treasury's reported 7% unrealized gain as of September 18, 2025, is stated to have "outperformed the C10 index overall," indicating a positive internal benchmark comparison for its initial crypto asset allocations. No specific external benchmarks or comparable companies are named for this performance.

Management Changes

Corporate Governance

Related Party Transactions

• YT Jia, Faraday Future's Founder and Global Co-CEO, is personally investing approximately $4 million in Qualigen Therapeutics, Inc., facilitated by an FFGP loan. This constitutes a related party transaction.
• Faraday Future will reimburse Qualigen Therapeutics for legal, accounting, and other professional fees incurred in connection with the PIPE transaction, up to a maximum of $500,000.

Stakeholder Impact

• Shareholders (Faraday Future): Potential for new revenue streams and value creation through diversification into crypto/Web3, but also introduces new risks associated with cryptocurrency volatility and regulatory uncertainty. Increased authorized shares provide flexibility but could lead to future dilution.
• Shareholders (Qualigen Therapeutics): Significant strategic shift from medical-related business to crypto/Web3, with new management and substantial investment from Faraday Future. This could lead to a re-rating of the stock based on the new business focus.
• Employees (Qualigen Therapeutics): Major change in business focus and management, potentially impacting existing roles and requiring new skill sets for the crypto/Web3 venture.
• Customers (Faraday Future): The "Dual Flywheel" strategy aims to connect EAI (Electric, AI, Internet) with crypto, potentially enhancing the user ecosystem for FF's vehicles.

Next Steps

• Closing of the PIPE transaction with Qualigen Therapeutics, Inc. on or about September 29, 2025.
• Qualigen to obtain stockholder approval for the transaction, including governance changes and share issuance, by October 29, 2025 (or November 28, 2025 if SEC review occurs).
• Qualigen to rebrand as CXC10, focusing on crypto and Web3 growth engines.
• Qualigen to file a registration statement (Form S-1 or S-3) within 45 days of September 19, 2025, to register for resale all securities issued in the PIPE.
• Qualigen to negotiate and enter into an advisory agreement with Mr. YT Jia as Chief Advisor within 30 days of closing.
• FX Super One Middle East Final Launch by end of October 2025.
• First deliveries of FX Super One in the Middle East expected in November 2025.
• Continued development and launch of CXC10's three growth engines: C10 value anchor, BesTrade DeAI Agent, and ecosystem tokens.

Key Dates

Recommendation

The strategic investment in Qualigen Therapeutics to launch a crypto and Web3 business, coupled with Faraday Future's significant ownership and management control, presents a compelling diversification strategy with high growth potential. The reported positive performance of Qualigen's C10 Treasury and the clear roadmap for the FX Super One MPV indicate operational progress. The approval of increased authorized shares and an expanded stock incentive plan provides financial flexibility and strengthens long-term incentive alignment. While new risks associated with crypto are introduced, the potential for 'Dual Flywheel synergy' and new financing channels could unlock substantial shareholder value, making this a strong buy for investors seeking exposure to both EV and emerging digital asset markets.

Keywords

Faraday Future, Qualigen Therapeutics, PIPE, Cryptocurrency, Web3, EV, Electric Vehicle, Strategic Investment, Corporate Governance, Stockholder Approval, FF Super One, C10 Treasury, Blockchain, AI, Financial Reporting